Switch theme
Sign up to access all valuation multiples
Diagnos Inc is engaged in the provision of software-based interpretation services to assist health specialists in the detection of diabetic retinopathy. The company provides image analysis services through CARA (Computer Assisted Retinal Analysis). It operates in the business segment of Healthcare services. The company has a business presence in Canada, the United States, Mexico, Chile, and others. The company's key revenue is derived from Canada.
1996
15
LTM Revenue $0.1M
Last FY EBITDA -$1.8M
$15.4M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Diagnos has a last 12-month revenue (LTM) of $0.1M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Diagnos achieved revenue of $0.1M and an EBITDA of -$1.8M.
Diagnos expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Diagnos valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $0.1M | XXX | $0.1M | XXX | XXX | XXX |
| Gross Profit | $0.1M | XXX | -$0.6M | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | -492% | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$1.8M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -1438% | XXX | XXX | XXX |
| EBIT | n/a | XXX | -$1.9M | XXX | XXX | XXX |
| EBIT Margin | n/a | XXX | -1523% | XXX | XXX | XXX |
| Net Profit | -$3.1M | XXX | -$2.3M | XXX | XXX | XXX |
| Net Margin | -4130% | XXX | -1834% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $2.0M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Diagnos's stock price is CAD 0 (or $0).
Diagnos has current market cap of CAD 20.9M (or $15.1M), and EV of CAD 21.4M (or $15.4M).
See Diagnos trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $15.4M | $15.1M | XXX | XXX | XXX | XXX | $-0.04 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Diagnos has market cap of $15.1M and EV of $15.4M.
Diagnos's trades at 85.9x EV/Revenue multiple, and -9.1x EV/EBITDA.
Equity research analysts estimate Diagnos's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Diagnos has a P/E ratio of -4.9x.
See valuation multiples for Diagnos and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $15.1M | XXX | $15.1M | XXX | XXX | XXX |
| EV (current) | $15.4M | XXX | $15.4M | XXX | XXX | XXX |
| EV/Revenue | 206.2x | XXX | 85.9x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -9.1x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | -8.6x | XXX | XXX | XXX |
| EV/Gross Profit | 206.2x | XXX | n/a | XXX | XXX | XXX |
| P/E | -4.9x | XXX | -7.1x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -10.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialDiagnos's revenue per employee in the last FY averaged $8K, while opex per employee averaged $0.1M for the same period.
Diagnos's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Diagnos's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Diagnos and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -948% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $8K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 1030% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Australian Clinical Labs | XXX | XXX | XXX | XXX | XXX | XXX |
| Clarity Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| CurveBeam AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Cyclopharm | XXX | XXX | XXX | XXX | XXX | XXX |
| Healius | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Diagnos acquired XXX companies to date.
Last acquisition by Diagnos was XXXXXXXX, XXXXX XXXXX XXXXXX . Diagnos acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Diagnos founded? | Diagnos was founded in 1996. |
| Where is Diagnos headquartered? | Diagnos is headquartered in Canada. |
| How many employees does Diagnos have? | As of today, Diagnos has 15 employees. |
| Is Diagnos publicy listed? | Yes, Diagnos is a public company listed on TSX. |
| What is the stock symbol of Diagnos? | Diagnos trades under ADK ticker. |
| When did Diagnos go public? | Diagnos went public in 2000. |
| Who are competitors of Diagnos? | Similar companies to Diagnos include e.g. Australian Clinical Labs, Clarity Pharmaceuticals, CurveBeam AI, Cyclopharm. |
| What is the current market cap of Diagnos? | Diagnos's current market cap is $15.1M |
| What is the current revenue of Diagnos? | Diagnos's last 12 months revenue is $0.1M. |
| What is the current EV/Revenue multiple of Diagnos? | Current revenue multiple of Diagnos is 206.2x. |
| Is Diagnos profitable? | Yes, Diagnos is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
